T1	DISO 652 654	PE
#1	AnnotatorNotes T1	C0242656; Disease Progression; Pathologic Function
T2	CHEM 115 124	nivolumab
#2	AnnotatorNotes T2	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 131 140	nivolumab
#3	AnnotatorNotes T3	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	CHEM 143 153	ipilimumab
#4	AnnotatorNotes T4	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	DISO 169 200	carcinoma microcítico de pulmón
T6	ANAT 194 200	pulmón
#5	AnnotatorNotes T6	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T7	PROC 242 281	Estudio de fase I/II sobre la seguridad
T8	CHEM 341 350	nivolumab
#6	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	CHEM 353 362	nivolumab
#7	AnnotatorNotes T9	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	CHEM 365 375	ipilimumab
#8	AnnotatorNotes T10	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	DISO 391 422	carcinoma microcítico de pulmón
T12	ANAT 416 422	pulmón
#9	AnnotatorNotes T12	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T13	DISO 465 496	Carcinoma microcítico de pulmón
T14	ANAT 490 496	pulmón
#10	AnnotatorNotes T14	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T15	DISO 580 583	CMP
T16	CHEM 951 972	pirrolobenzodiazepina
T17	CHEM 714 721	platino
#11	AnnotatorNotes T17	C0032207; platinum; Element, Ion, or Isotope
T18	ANAT 781 789	hepática
#12	AnnotatorNotes T18	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T19	ANAT 792 797	renal
#13	AnnotatorNotes T19	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T20	DISO 834 860	Enfermedad autoinmunitaria
#14	AnnotatorNotes T20	C0004364; Autoimmune Diseases; Disease or Syndrome
T21	PROC 892 903	Tratamiento
#15	AnnotatorNotes T21	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T22	CHEM 933 940	fármaco
#16	AnnotatorNotes T22	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T23	ANAT 179 190	microcítico
#17	AnnotatorNotes T23	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T24	ANAT 401 412	microcítico
#18	AnnotatorNotes T24	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T25	ANAT 475 486	microcítico
#19	AnnotatorNotes T25	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T26	PROC 625 635	histología
#20	AnnotatorNotes T26	C0344441; Histology Procedure; Laboratory Procedure
T27	PROC 638 647	citología
#21	AnnotatorNotes T27	C1305671; Cytology procedure; Laboratory Procedure
T28	PROC 678 703	régimen quimioterapéutico
T29	CHEM 285 308	rovalpituzumab tesirina
T30	CHEM 59 82	rovalpituzumab tesirina
T31	CHEM 974 977	PBD
T32	Date 13 17	2016
T33	LIVB 157 164	adultos
#22	AnnotatorNotes T33	C0001675; Adult; Age Group
T34	LIVB 379 386	adultos
#23	AnnotatorNotes T34	C0001675; Adult; Age Group
T35	LIVB 545 551	Adulto
#24	AnnotatorNotes T35	C0001675; Adult; Age Group
T36	Age 555 576	18 años de edad o más
T38	Spec_cue 880 888	presunta
T37	PHYS 759 797	Función hematológica, hepática y renal
#25	AnnotatorNotes T37	C0221130; Hematologic function; Organ or Tissue Function + C0232804; Renal function; Organ or Tissue Function; + C0232741; Liver function; Organ or Tissue Function
T39	PROC 725 741	Estado funcional
#26	AnnotatorNotes T39	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
A1	Population_data T33 Age
A2	Assertion T20 Speculated
A3	Population_data T35 Age
A4	Population_data T34 Age
A5	Status T28 History_of
A6	Status T20 History_of
A7	Status T17 History_of
A8	Status T21 History_of
A9	Status T22 History_of
A10	Status T16 History_of
A11	Status T31 History_of
#27	AnnotatorNotes T30	C4507507; rovalpituzumab tesirine; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor 
#28	AnnotatorNotes T29	C4507507; rovalpituzumab tesirine; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor 
#29	AnnotatorNotes T7	C1705187; Safety Study; Research Activity + C1519043; Phase I/II Trial; Research Activity
#30	AnnotatorNotes T28	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
#31	AnnotatorNotes T16	C1260204; pyrrolobenzodiazepine; Organic Chemical 
#32	AnnotatorNotes T31	C1260204; pyrrolobenzodiazepine; Organic Chemical 
R1	Combined_with Arg1:T30 Arg2:T2	
R2	Combined_with Arg1:T30 Arg2:T3	
R3	Combined_with Arg1:T3 Arg2:T4	
R4	Experiences Arg1:T33 Arg2:T30	
R5	Experiences Arg1:T33 Arg2:T3	
R6	Experiences Arg1:T33 Arg2:T5	
R7	Location_of Arg1:T6 Arg2:T5	
R8	Location_of Arg1:T23 Arg2:T5	
T40	Quantifier_or_Qualifier 204 221	estadio extendido
#33	AnnotatorNotes T40	C1522484; metastatic qualifier; Functional Concept | C0036525; Metastatic to; Functional Concept
R9	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T40	
T41	Quantifier_or_Qualifier 426 443	estadio extendido
#34	AnnotatorNotes T41	C1522484; metastatic qualifier; Functional Concept | C0036525; Metastatic to; Functional Concept
R10	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T41	
T42	Quantifier_or_Qualifier 500 517	estadio extendido
#35	AnnotatorNotes T42	C1522484; metastatic qualifier; Functional Concept | C0036525; Metastatic to; Functional Concept
R11	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T42	
T43	Quantifier_or_Qualifier 587 604	estadio extendido
#36	AnnotatorNotes T43	C1522484; metastatic qualifier; Functional Concept | C0036525; Metastatic to; Functional Concept
R12	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T43	
R13	Location_of Arg1:T14 Arg2:T13	
R14	Location_of Arg1:T25 Arg2:T13	
R15	Location_of Arg1:T12 Arg2:T11	
R16	Location_of Arg1:T24 Arg2:T11	
#37	AnnotatorNotes T11	C0149925; Small cell carcinoma of lung; Neoplastic Process
#38	AnnotatorNotes T5	C0149925; Small cell carcinoma of lung; Neoplastic Process
#39	AnnotatorNotes T13	C0149925; Small cell carcinoma of lung; Neoplastic Process
#40	AnnotatorNotes T15	C0149925; Small cell carcinoma of lung; Neoplastic Process
R17	Combined_with Arg1:T29 Arg2:T8	
R18	Combined_with Arg1:T29 Arg2:T9	
R19	Combined_with Arg1:T9 Arg2:T10	
R20	Experiences Arg1:T34 Arg2:T29	
R21	Experiences Arg1:T34 Arg2:T11	
R22	Has_Age Arg1:T35 Arg2:T36	
R25	Before Arg1:T15 Arg2:T1	
R26	After Arg1:T1 Arg2:T28	
T44	Quantifier_or_Qualifier 666 677	al menos un
R27	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T44	
R28	Used_for Arg1:T17 Arg2:T28	
T45	Result_or_Value 750 755	0 o 1
T46	CONC 742 746	ECOG
#41	AnnotatorNotes T46	C1520224; ECOG performance status; Intellectual Product
R29	Used_for Arg1:T46 Arg2:T39	
R30	Has_Result_or_Value Arg1:T46 Arg2:T45	
T47	Observation 759 806	Función hematológica, hepática y renal adecuada
#42	AnnotatorNotes T47	C3810095; Normal hematologic parameters; Finding (?) + C1848676; Normal liver function; Finding + C0232805; Normal renal function; Finding
R31	Location_of Arg1:T18 Arg2:T37	
R32	Location_of Arg1:T19 Arg2:T37	
R33	Location_of Arg1:T18 Arg2:T47	
R34	Location_of Arg1:T19 Arg2:T47	
R35	Speculation Arg1:T38 Arg2:T20	
T48	Quantifier_or_Qualifier 861 867	activa
#43	AnnotatorNotes T48	C0679217; Active State; Idea or Concept
R36	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T48	
R37	Used_for Arg1:T22 Arg2:T21	
R38	Used_for Arg1:T16 Arg2:T21	
R39	Used_for Arg1:T31 Arg2:T21	
A12	Experiencer T35 Patient
A13	Experiencer T33 Patient
A14	Experiencer T34 Patient
